Which of the following is reported as an adverse effect of evinacumab?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

The main idea here is recognizing which adverse effect is most consistently reported with evinacumab. Evinacumab is a monoclonal antibody that inhibits ANGPTL3 and is used to lower LDL cholesterol and triglycerides. In clinical trials, the most commonly reported adverse event is nasopharyngitis, an upper respiratory tract infection of the nose and throat. This pattern—nasopharyngitis appearing more frequently than other systemic symptoms like nausea, fatigue, or insomnia—is typical for monoclonal antibody therapies given by infusion, where minor upper respiratory infections are a common and generally manageable side effect.

So, nasopharyngitis is the best answer because it reflects the typical trial-observed adverse event profile for evinacumab, whereas the other options occur less consistently or are less characteristic of this specific therapy.